AI in Healthcare
The latest on artificial intelligence transforming medicine
News stories discovered and organized by an automated pipeline. Covering clinical deployments, research breakthroughs, regulation, and industry developments.
Novo Nordisk’s OpenAI Deal Shows Big Pharma Still Wants a Shortcut to Discovery
Novo Nordisk’s partnership with OpenAI reflects the increasing willingness of major drugmakers to use general-purpose AI companies in core R&D workflows. The deal highlights a growing belief that large language and multimodal systems can accelerate research, even as the industry still lacks clear evidence of broad clinical payoff.
Why Real-Time Kinetics Could Be the Missing Link in AI-Driven Drug Discovery
A new focus on real-time kinetics reflects a growing realization that AI needs better experimental inputs, not just better models. In drug discovery, speed is useful only if it is paired with measurements that capture how compounds actually behave over time.
Novo Nordisk and OpenAI Strike a Broad AI Pact for Drug Discovery and Beyond
Novo Nordisk’s agreement with OpenAI is a sign that major drugmakers are moving AI from isolated research experiments into core R&D operations. The deal appears designed to spread AI across discovery, manufacturing, and corporate workflows, not just one lab team.
BullFrog AI Partnership Highlights the New Pressure on Smaller Discovery Platforms
BullFrog AI’s newly announced drug-discovery partnership underscores how smaller AI companies are seeking validation through targeted collaborations rather than sweeping platform claims. The move reflects a broader market reality: in healthcare AI, commercial credibility increasingly comes from proving fit on specific programs.
Insilico-Lilly deal shows big pharma still sees AI as a pipeline multiplier, not a side bet
A reported multibillion-dollar deal between Insilico Medicine and Eli Lilly underscores continued pharmaceutical appetite for AI-enabled drug discovery. The scale suggests AI is being valued not as experimental tooling but as a potentially material lever on pipeline speed, hit quality, and portfolio optionality.
AI in Drug Discovery Xchange Reflects an Industry Moving From Curiosity to Operating Model
The prominence of the AI in Drug Discovery Xchange in San Francisco reflects how quickly the field has shifted from experimental side projects to a central R&D agenda. Conferences now matter not just as networking venues, but as signals of what problems the sector believes are commercially urgent.
Merck’s KERMT Signals Big Pharma’s Shift From AI Pilots to Foundation Models for Drug Discovery
Merck’s disclosure of its KERMT model offers a clearer view into how major drugmakers are building proprietary AI systems tuned for chemistry and biology workflows. The significance is less the branding of one model than the evidence that large pharma increasingly sees internal foundation models as strategic R&D infrastructure.
Insilico and Servier Sign $888 Million AI Cancer Discovery Pact
Insilico Medicine and Servier have entered a cancer R&D collaboration valued at up to $888 million, with Insilico leading AI-driven discovery for challenging oncology targets and Servier handling clinical validation and commercialization. The deal underscores how major drugmakers are increasingly treating AI not as a side capability but as a front-end engine for target selection and molecule generation.
How this works
Discover
An automated pipeline searches the web for significant AI healthcare news across clinical, research, regulatory, and industry domains.
Structure
The pipeline turns source material into concise, readable stories with categories, tags, and context that make the feed easier to scan.
Publish
Stories are deduplicated, stored, and published to this site. The pipeline runs automatically to keep coverage current.